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This topic addresses the treatment of newly diagnosed patients with favorable prognosis stage I 
and II Hodgkin lymphoma. In most cases, combined modality therapy (chemotherapy followed by 
involved site radiation therapy) constitutes the current standard of care. The American College of 
Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions 
that are reviewed annually by a multidisciplinary expert panel. The guideline development and 
revision include an extensive analysis of current medical literature from peer-reviewed journals 
and the application of well-established methodologies (RAND/UCLA Appropriateness Method 
and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate 
the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those 
instances where evidence is lacking or equivocal, expert opinion may supplement the available 
evidence to recommend imaging or treatment. By combining the most recent medical literature 
and expert opinion, this revised guideline can aid clinicians in the appropriate use of combined 
modality therapy for favorable prognosis stage I and II Hodgkin lymphoma. Increasing 
information about the late effects of treatment has led to attempts to decrease toxicity by using less 
chemotherapy (decreased duration and/or intensity or different agents) and less radiation therapy 
(reduced volume and/or dose) while maintaining excellent efficacy.
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SUMMARY OF LITERATURE REVIEW
Prognostic Factors
The definition of favorable prognosis stage I and II Hodgkin lymphoma (HL) varies 
somewhat among major cooperative groups, as outlined in Table 1. All 3 cooperative groups 
exclude patients with large mediastinal masses; however, the definitions vary slightly. The 
German Hodgkin Study Group (GHSG) and National Comprehensive Cancer Network 
(NCCN) divide the maximum width of the mass on an upright posteroanterior chest 
radiograph by the maximum intrathoracic diameter to determine the mediastinal mass ratio. 
The European Organisation for Research and Treatment of Cancer (EORTC) uses the 
intrathoracic diameter at the T5-6 vertebral body level as the denominator to determine the 
mediastinal tumor ratio. The NCCN guidelines also define nonmediastinal bulk as disease ≥ 
10 cm on an axial computed tomography (CT) scan.1 All 3 groups consider the erythrocyte 
sedimentation rate (ESR) value and systemic symptoms, but defining criteria differ. Both the 
GHSG and the EORTC define favorable disease using an ESR of <50 mm/h in the absence 
of “B” symptoms (significant unexplained fever, night sweats, or unexplained weight loss 
exceeding 10% of body weight during the previous 6 mo) and an ESR of <30 mm/h in the 
presence of B symptoms. The NCCN definition sets the ESR limit at 50 for all and excludes 
patients with B symptoms. Regarding the number of involved sites, the groups differ in that 
the GHSG criteria allow up to 2 sites of involvement and the EORTC and NCCN criteria 
allow for up to 3 sites. In addition, the GHSG criteria exclude patients with extranodal 
disease, the EORTC has an age requirement (age ≤50 y), and the NCCN further excludes 
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patients with bulky disease >10 cm.1–3 In interpreting trial results, it is important to pay 
attention to the risk group definition, as the results are applicable only to patients who fit the 
strict and specific inclusion criteria.
Historic Trials That Established Combined Modality Therapy as Standard of Care
Large, single-institutional studies of patients treated in the 1960s and 1970s demonstrated 
>80% actuarial 10-year to 15-year freedom from relapse and <10% mortality rates from HL 
following mantle and para-aortic irradiation for pathologically staged IA to IIA patients.4–6 
Increasing concern for the long-term consequences of treatment7–15 prompted many 
investigators to evaluate new approaches for early-stage HL. As outlined below, this 
ultimately established a combined modality approach using involved field radiation therapy 
(IFRT) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as the standard of 
care, with the Stanford V regimen (nitrogen mustard, doxorubicin, vincristine, vinblastine, 
etoposide, bleomycin, prednisone, and radiation) as an acceptable alternative.
In the GHSG HD7 trial, patients with early-stage favorable HL were randomized to receive 
either extended-field radiation therapy (EFRT) or 2 cycles of ABVD followed by EFRT. 
Patients in the combined modality arm had a significantly higher rate of freedom from 
treatment failure than those in the EFRT alone arm (7-year rates, 88% vs. 67%, P<0.0001). 
There was no significant difference in overall survival (OS) between the 2 arms (7-year 
rates, 94% vs. 92%, P = 0.43).16 The Southwest Oncology Group and Cancer and Leukemia 
Group B conducted a similar study and found that the combined modality arm had a 
significantly higher failure-free survival rate than patients in the subtotal lymphoid 
irradiation arm (3-year rate, 94% vs. 81%, P<0.001).17 These 2 trials showed that the 
addition of chemotherapy improves early disease control outcomes in patients treated with 
EFRT or subtotal lymphoid radiation therapy (RT).
Other trials also tested the use of combined modality therapy versus radiation alone. EORTC 
H7 randomized early-stage favorable patients to receive either subtotal nodal irradiation 
alone (36 to 40 Gy) or 6 cycles of epirubicin, bleomycin, vinblastine, and prednisone 
(EBVP) followed by IFRT (36 to 40 Gy). Patients in the combined modality arm had a 
significantly higher rate of event-free survival compared with the RT alone arm (10-year 
rates, 88% vs. 78%, P = 0.01). Again, there was no significant difference in OS between the 
2 arms (10-year rates, 92% vs. 92%, P = 0.79). This trial demonstrated that the previous 
standard of EFRT alone could be replaced by combined modality therapy with IFRT in 
favorable prognosis stage I or II HL patients, resulting in improved event-free survival and 
similar OS.18 In a subsequent trial, EORTC H8F, 543 patients with supradiaphragmatic stage 
I or II HL and favorable prognostic features were randomized to receive either subtotal nodal 
irradiation or 3 cycles of mechlorethamine, vincristine, procarbazine, and prednisone 
combined with doxorubicin, bleomycin, and vinblastine (ABV) followed by IFRT.19 Patients 
in the combined modality arm had a significantly higher event-free survival rate than did 
patients in the subtotal nodal irradiation arm (98% vs. 74%, P<0.001).
Few randomized trials have compared different chemotherapy regimens in combination with 
RT for the treatment of patients with favorable prognosis early-stage HL. The ABVD 
regimen has been used most commonly, based in large part upon the extrapolation of trials 
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that compared ABVD with other regimens in patients with more advanced HL. Specifically, 
ABVD has demonstrated superior efficacy and less toxicity when compared with 
mechlorethamine, vincristine, procarbazine, and prednisone in patients with both 
unfavorable prognosis early-stage and advanced-stage HL.20,21
The Stanford V regimen is a highly effective and well-tolerated alternative to ABVD. It was 
initially developed for patients with locally extensive and advanced HL.22 However, an 
abbreviated 8-week regimen followed by 30-Gy IFRT was studied in the phase II Stanford 
G4 trial of early-stage IA/IIA nonbulky HL patients. The therapy was well tolerated and at a 
median follow-up of 10 years the freedom from progression and OS rates were 94% and 
94%, respectively.23
As noted above, in most of the modern trials combined modality therapy has resulted in 
higher rates of freedom from recurrence but no difference in OS. Given the effectiveness of 
salvage with chemotherapy after failure of RT, this lack of apparent survival advantage may 
be due in large part to the relatively short follow-up of those studies. Long-term follow-up of 
the EORTC H8F trial does demonstrate that although patients in both arms had similar 
response rates and cumulative risk for second cancers, patients who received combined 
modality therapy had a significant 10-year OS benefit when compared with those who 
received RT alone (10-year rates, 97% vs. 92%, P = 0.001).19 A recent meta-analysis 
comparing chemotherapy alone to combined chemotherapy and RT for early-stage HL 
patients likewise demonstrated both a recurrence-free and OS advantage to combined 
modality therapy.24
Contemporary Approaches
The cumulative experience as outlined above established a combined modality approach of 4 
cycles of ABVD with 30 Gy of IFRT as the standard of care for favorable early-stage HL, 
with long-term follow-up confirming excellent outcomes.25
It is important to note that the data on late effects after HL are largely based on studies of 
patients treated decades ago with outdated RT techniques, using much larger treatment fields 
and higher doses. There is ample evidence that the risks of late complications are directly 
related to radiation dose26–31 and field size.8,32 Similarly, modern chemotherapy regimens 
that exclude alkylators are expected to further reduce the risk of late effects, specifically 
leukemia and infertility.33,34 Certainly 4 cycles of ABVD followed by 30 Gy of IFRT would 
be expected to decrease late effects in the years following treatment, relative to antiquated 
regimens. Although long-term toxicity data from this regimen mature, contemporary 
approaches are aimed at reducing the late effects from therapy even further while 
maintaining excellent efficacy.
Trials Evaluating Optimal Number of Cycles of Chemotherapy and Combinations of Agents
The use of fewer cycles of chemotherapy could potentially reduce long-term toxicity from 
combined modality therapy. Results were published recently from the GHSG HD10 trial.35 
In this trial 1371 stage I or II favorable prognosis HL patients were randomized to 1 of 4 
arms: (1) 4 cycles of ABVD followed by 30 Gy of IFRT, (2) 4 cycles of ABVD followed by 
20 Gy of IFRT, (3) 2 cycles of ABVD followed by 30 Gy of IFRT, and (4) 2 cycles of 
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ABVD followed by 20 Gy of IFRT. At a median follow-up of 7.5 years, there were no 
significant differences in 5-year progression-free survival (PFS) or OS. However, there were 
significant differences in World Health Organization grade III or IV toxicity between 4 and 2 
cycles of ABVD in the overall number of events (52% vs. 33%), including leukopenia (24% 
vs. 15%), infections (5.1% vs. 1.7%), and hair loss (28% vs. 15%). It is certainly possible 
that late cardiac disease rates will increase in the 4-cycle versus 2-cycle ABVD arms as well.
The GHSG 13 trial investigated whether certain agents could be omitted from the ABVD 
regimen in patients treated with combined modality therapy. In this 4-arm randomized study, 
patients with stage I or II HL were treated with either ABVD, ABV, doxorubicin vinblastine 
and dacarbazine (AVD), or doxorubicin, vinblastine (AV), all followed by 30 Gy of IFRT. 
The 5-year freedom from treatment failure was 93.1%, 81.4%, 89.2%, and 77.1% with 
ABVD, ABV, AVD, and AV, respectively. Compared with ABVD, inferiority of the 
dacarbazine-deleted variants was detected, with 5-year differences of −11.5% (95% 
confidence interval [CI], 18.3 to −4.7) for ABV and −15.2% (−23.0 to −7.4) for AV. 
Noninferiority of AVD compared with ABVD could also not be detected, with a 5-year 
difference of −3.9% (−7.7 to −0.1). The study concluded that dacarbazine cannot be omitted 
from ABVD without substantial loss of efficacy and bleomycin cannot be safely omitted 
either.36
The previously mentioned Stanford G4 trial demonstrated that an abbreviated 8-week course 
of the Stanford V regimen results in efficacy comparable with that seen in the GHSG HD10 
trial. This is particularly impressive given that a significant proportion of patients on the 
Stanford G4 trial had unfavorable risk factors that would have excluded them from inclusion 
in the GHSG HD10 trial. It is possible that the subset of favorable patients in the G4 trial 
would do well with further reduction of therapy, and so the G5 trial is evaluating a modified 
8-week version in which nitrogen mustard is replaced by cyclophosphamide and the RT dose 
is reduced from 30 Gy to 20 Gy while the volume is reduced to involved node radiation 
therapy (INRT).37 Although data from G5 mature, it is worthwhile to note that although the 
cumulative doses of doxorubicin are similar between the abbreviated Stanford V regimen 
used in the G4 trial and 2 cycles of ABVD, the bleomycin dose was 50% lower in the 
Stanford regimen. Therefore, in situations where is it desirable to limit exposure to 
bleomycin, this regimen may be particularly attractive.
Trials Evaluating Optimal Radiation Dose
Two randomized trials have investigated the optimal radiation dose in favorable prognosis 
stage I or II HL patients treated with combined modality therapy.
In the GHSG HD10 trial discussed above, there was no significant difference in freedom 
from treatment failure (P = 1.00), PFS (P = 0.98), or OS (P = 0.61) between the groups 
treated with 20 and 30 Gy of IFRT. The 5-year rate of freedom from treatment failure was 
93% with 20 Gy or 30 Gy of IFRT. However, there were significant differences in World 
Health Organization grade III or IV between 30 and 20 Gy IFRT in overall events (8.7% vs. 
2.9%), including dysphagia (3% vs. 2%) and mucositis (3.4% vs. 0.7%).35
Dhakal et al. Page 5













In the EORTC H9F trial, patients were treated with 6 cycles of EBVP and those attaining a 
complete response were randomized to 1 of 3 arms: (1) no radiation, (2) 20-Gy IFRT, and 
(3) 36-Gy IFRT.38 The no radiation arm was closed early, as discussed in the section “Trials 
Evaluating Chemotherapy Alone.” The event-free survival rates of the 20-Gy and 36-Gy 
arms were 84% and 87%, respectively. Mature results of this trial will determine whether the 
lower dose of 20 Gy can be used in patients with favorable disease as per the EORTC 
criteria.
Preliminary data suggest that 20 Gy may be adequate in well-selected patients treated with 
the abbreviated Stanford V regimen as well.37
Trials Evaluating Optimal Radiation Field Size, Volume, and Technique
Over the past few decades, with advances in systemic therapy and radiation treatment 
planning and delivery, as well as an improved understanding of the late effects of therapy, 
there has been a successful effort to decrease the radiation field while maintaining efficacy.
The original total nodal and extended radiation fields were based on bony anatomy and 2-
dimensional RT planning. These radiation fields were replaced by IFRT, which substantially 
reduced the treatment volumes. Although no randomized trial has compared IFRT and EFRT 
in favorable prognosis patients, multiple trials have addressed this issue in unfavorable 
prognosis patients.19,25,39
There has been growing interest in further refining the radiation treatment technique by 
using volume-based, 3-dimensional treatment planning to treat only the initially involved 
nodes.40 Initial results are promising. A retrospective study from Canada compared 96 
patients treated with IFRT and 102 patients treated with INRT, all of whom received 
combined modality therapy.41 In this study, INRT was defined as prechemotherapy nodal 
volumes with margins ≤5 cm. Five relapses occurred in the IFRT group and 3 in the INRT 
group. There were no locoregional or marginal relapses in the INRT group. Moreover, there 
was no significant difference in OS or PFS between the IFRT and INRT groups. An 
additional retrospective analysis of 97 patients with stage I to II HL treated with ABVD plus 
INRT and followed for a median of 50 months reported an estimated 4-year freedom from 
disease progression of 96.4% (95% CI, 92.4%-100%)42
Of note, the method by which the treatment volume used in INRT is defined varies between 
different groups. For example, the EORTC recommends the use of prechemotherapy 
positron emission tomography (PET)/CT in the radiation treatment planning position as well 
as a posttreatment scan to determine the clinical target volume. The expansion from clinical 
target volume to planning target volume is 1 cm isotropically.40 In contrast, the GHSG does 
not require the use of pretreatment PET/CT. Their expansion is from the clinical target 
volume to the planning target volume by 1 to 3 cm, depending on the anatomic location.43
Clearly, INRT is technically very challenging and for many practitioners the above 
requirements would preclude its use. The International Lymphoma Radiation Oncology 
Group (ILROG) of experts has recently published guidelines that propose a new RT 
technique, termed involved site radiation therapy (ISRT), that is similar to INRT but uses 
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more conservative parameters for determination of the volume at risk.44 This technique 
allows for uncertainties due to a lack of ideal imaging (eg, lack of prechemotherapy PET and 
simulation before chemotherapy as noted above). It is important to note that INRT is 
essentially a form of ISRT with more stringent requirements for prechemotherapy imaging 
studies in addition to postchemotherapy imaging, including simulation for treatment 
planning. Therefore, disease control following ISRT is expected to be at least as good as that 
obtained with INRT. In addition, these reduced treatment volumes can be safely and 
efficiently combined with modern radiation treatment techniques such as intensity-
modulated RT45,46 or proton therapy,47,48 as well as respiratory gating,35,40 which should 
further reduce late radiation toxicity.49
Additional studies are needed to establish the role of INRT for favorable prognosis HL. The 
ongoing EORTC H10F trial, discussed later, has already incorporated INRT in both the 
standard and experimental arms, and INRT is the volume used in the Stanford G5 trial as 
well.37 A new trial by the GHSG HD17 is comparing IFRT versus INRT in early-stage 
patients. In the meantime, the ISRT guidelines published by the ILROG should be followed.
Trials Evaluating Chemotherapy Alone
Since RT has been associated with long-term side effects such as second malignancies and 
cardiotoxicity, some studies have evaluated whether early-stage HL patients could be treated 
with chemotherapy alone, thereby excluding RT. This remains highly controversial, and 
although several trials have been conducted, the results are difficult to interpret because of 
issues related to trial design and patient accrual and characteristics, as well as highly 
variable chemotherapy regimens and RT fields and volumes.
In a randomized trial at the Memorial Sloan Kettering Cancer Center, 152 patients with stage 
IA to IIIA nonbulky HL were treated with either 6 cycles of ABVD or 6 cycles of ABVD 
followed by RT to a dose of 36 Gy (IFRT in 14%, modified extended field in the rest).50 
This trial did not detect any significant difference between the chemotherapy and combined 
modality arms for the 5-year rates of freedom from progression (81% vs. 86%, P = 0.61) or 
OS (90% vs. 97%, P = 0.08). However, this trial closed early because of poor accrual and 
was not powered to detect any difference <20%.
More recently, the National Cancer Institute of Canada and the Eastern Cooperative 
Oncology Group conducted a randomized trial on 405 patients with nonbulky stage I or IIA 
HL.51 Favorable risk patients were randomized to receive either subtotal nodal irradiation or 
2 cycles of ABVD followed by CT-based restaging and an additional 2 or 4 cycles of 
chemotherapy based on response. Among the favorable risk patients, there was no difference 
between the 2 arms in either disease-free survival or OS, which was estimated at 94% after 
12 years. Of note, this trial compared chemotherapy alone to RT alone, not chemotherapy 
versus combined modality therapy, which has clearly been shown to be superior to RT alone. 
More importantly, the subtotal nodal irradiation field used in this trial was replaced decades 
ago by smaller fields precisely because of concerns regarding the potentially fatal late effects 
that were seen in this trial. Moreover, the radiation dose was higher (35 Gy) than the current 
standard. Furthermore, this trial was conducted before the widespread availability of PET, so 
both initial staging and subsequent treatment response evaluations were CT based. 
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Therefore, the results of this trial are difficult to extrapolate to contemporary approaches 
because it compared an experimental chemotherapy only arm to an antiquated RT only 
“control” arm. Nonetheless, the excellent disease-free survival and OS achieved by 
chemotherapy alone are certainly impressive and noteworthy in their own right. Risk-
adapted chemotherapy only-based approaches are an active area of investigation, as noted in 
the section “Response-Adapted Therapy Based on Early PET Results.”
Data do exist to support caution in excluding RT in the treatment of early-stage HL. In the 
EORTC H9F trial, patients were treated with 6 cycles of EBVP, and those attaining a 
complete response were randomized to 1 of 3 arms: (1) no-RT, (2) 20 Gy of IFRT, and (3) 36 
Gy of IFRT.38 The no-RT arm of the trial was forced to close early after predefined stopping 
rules were met. The event-free survival rate was significantly lower in the no-RT arm (4-year 
rate, 70%) compared with the 20-Gy (84%) and 36-Gy (87%) arms (P<0.001). In addition, 
several studies with predominately pediatric patients and a significant proportion of later-
stage disease have also demonstrated inferior outcomes when IFRT was omitted.52,53 In a 
recent meta-analysis that included randomized trials in early-stage patients comparing 
chemotherapy alone versus the same chemotherapy and RT, combined modality therapy was 
associated with a significantly improved tumor control rate (hazard ratio [HR] =0.41, 
P=0.0003), which translated into a significant OS benefit (HR =0.4, P<0.00001).24 Lastly, an 
analysis of the National Cancer Data Base of 20,600 patients with early-stage HL found that 
a combined modality approach was associated with an improved OS (HR = 0.61; 95% CI, 
0.53-0.70) compared with chemotherapy alone. Of particular concern, the proportion of 
patients who were treated with chemotherapy alone steadily increased from 2003 (40.6%) to 
2011 (54.8%) and treatment selection was significantly influenced by sex, race, and 
socioeconomic factors.54
Response-Adapted Therapy Based on Early PET Results
PET scans have become well established as standard of care in the initial staging and 
posttherapy evaluation of patients with HL. In addition, multiple studies have shown that 
interim PET results are highly predictive of treatment outcome.55–58 Naturally, this has led 
to investigations of the use of PET/CT data for early response-adapted therapy, with 
therapeutic stratification, often the omission of RT after chemotherapy, based on interim 
results. Picardi et al59 conducted one of the earlier randomized trials addressing the question 
of whether RT can be omitted if a complete response by PET is achieved after chemotherapy 
in patients with HL. Patients with disease size of ≥ 5 cm were included in this trial. One 
hundred sixty patients who had a complete response to induction chemotherapy but residual 
mass and PET-negative scan were randomized to undergo either observation or consolidative 
RT. Patients in the observation arm had a significantly inferior event-free survival rate (86%) 
compared with those in the RT arm (96%, P = 0.03). These results suggest that negative PET 
scans cannot be reliably used to exclude patients from RT.
Three prospective PET-adapted clinical trials on early-stage HL are exploring the possibility 
of omitting RT in patients with negative interim PET results. It is important to note that these 
trials use standardized criteria for PET/CT scan interpretation (Deauville criteria) that grade 
uptake relative to internal structures (thereby minimizing inter-reader subjectivity and 
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interdevice inconsistency because the patient serves as his or her own control) as follows: (1) 
no uptake; (2) uptake ≤ mediastinum; (3) uptake > mediastinum but ≤ liver; (4) uptake > 
liver; and (5) uptake > liver and new sites of disease. However, the study inclusion criteria 
vary.
In the EORTC H10F trial, all early-stage favorable HL patients are treated initially with 2 
cycles of ABVD followed by a PET scan. Regardless of PET scan results, all patients 
randomized to the standard arm receive a third cycle of ABVD and INRT. Patients on the 
experimental arm receive response-adapted therapy based on the PET scan results as 
follows: those with a negative PET scan (as defined by a score of 1 or 2 using the Deauville 
criteria) receive an additional 2 cycles of ABVD, and those who had a positive PET scan 
receive 2 cycles of dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, and prednisone followed by INRT. On the basis of recent interim 
analysis, it was determined that the experimental arm of omitting RT in the setting of 
negative PET after 2 cycles of ABVD was unlikely to be noninferior to the standard arm of 
combined modality therapy. At the recommendation of an independent data-safety 
monitoring board, the experimental arm of no-RT was closed and all patients on the trial are 
to receive INRT.60 The portion of the experimental arm using dose-escalated bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in 
patients with PET-positive disease after 2 cycles of ABVD is still ongoing.
The RAPID trial, a multicenter trial in the United Kingdom, explored response-adapted 
therapy. Its eligibility criteria differ in that it includes stage I (33%) and II (67%) patients 
without B symptoms or mediastinal bulk on presentation, and only 62% had favorable 
prognosis disease as defined by the EORTC criteria. All patients received 3 cycles of ABVD 
followed by a PET scan, which was negative in 74.7% of patients as defined by a score of 1 
or 2 using the Deauville criteria. These PET-negative patients were then randomly assigned 
to IFRT to a dose of 30 Gy versus no further therapy. At a median of 60 months of follow-up 
after randomization, the 3-year PFS rate was 94.6% (95% CI, 91.5-97.7) in the RT group 
and 90.8% (95% CI, 86.9-94.8) in the group that received no further therapy, with an 
absolute risk difference of −3.8% points (95% CI, −8.8 to 1.3).61 Despite the fact that early-
stage HL patients on this study who had a negative PET after 3 cycles of ABVD had a very 
good prognosis either with or without consolidation RT, it should be noted that this was a 
statistically negative trial, as the study did not demonstrate the noninferiority of the strategy 
of no further treatment after chemotherapy with regard to PFS.
In the GHSG HD16 trial, all early favorable prognosis HL patients are initially treated with 
2 cycles of ABVD followed by a PET scan. Regardless of PET scan results, all patients 
randomized to the standard arm receive 2 additional cycles of ABVD followed by 20-Gy 
IFRT. Patients on the experimental arm receive response-adapted therapy based on the PET 
scan as follows: those with a negative PET scan receive 2 additional cycles of ABVD 
followed by observation and those with a positive PET scan receive 2 additional cycles of 
ABVD followed by 20-Gy IFRT. Preliminary results are pending.
These trials will further clarify whether PET response can be used to guide treatment for 
HL. It is important to note that although these studies were designed in an effort to decrease 
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late effects and mortality associated with therapy, because the primary end point is PFS and 
the follow-up is limited, they directly address neither late effects nor survival. Therefore, 
changes in therapy (either changing chemotherapy or omitting RT) based on PET response 
for early-stage patients should be recommended with caution after careful consideration and 
preferably as part of a clinical trial, at least until these preliminary data mature (Tables 2–5).
Nodular Lymphocyte-Predominant HL
Nodular lymphocyte-predominant HL (NLPHL) is a rare disease that represents only about 
5% of all HLs. It has distinct histological features first described in the 1940s; however, it 
was not formally recognized as a separate disease entity until the 1994 Revised European-
American Classification of Lymphoid Neoplasms. In any event, one must confirm the 
diagnosis of NLPHL given that up to one half of patients who were initially diagnosed at 17 
large academic centers in Europe and America with NLPHL were reclassified upon expert 
review as having classical HL (most frequently the lymphocyte-rich subtype).62 Because of 
the rarity of NLPHL, prospective clinical trial data in this subgroup are limited. However, 
based on retrospective series, small prospective studies, and more recently a comprehensive 
analysis from the GHSG based on HD4 and HD12,63 it is apparent that the clinical 
presentation and natural history of NLPHL differ compared with its classical counterpart. 
Patients with NLPHL most frequently present with early-stage disease involving peripheral 
sites, as well as a significantly different natural history characterized by frequent relapses, 
but an overall very good prognosis. In addition, unlike in classical HL, the malignant cells of 
NLPHL universally express CD20.
Because of its rarity, there is no standardized treatment for NLPHL. However, the early 
presentation in over 80% of patients, its indolent, relapsing nature, and the recognition that a 
greater proportion of patients were dying from treatment-related complications rather than 
disease progression have led to the increasing use of less aggressive therapeutic approaches.
The GHSG recently published long-term results of an analysis of 256 patients with stage IA 
NLPHL who had been treated on one of their protocols between 1988 and 2009.64 Twenty-
seven patients had been treated with 4 weekly standard doses of rituximab, 49 had been 
treated with EFRT, and 108 with IFRT; the remaining 72 patients had received combined 
modality treatment. At 8 years, PFS and OS were 88.5% and 98.6% for combined modality 
treatment, 84.3% and 95.7% for EFRT, and 91.9% and 99.0% for IFRT, respectively. 
Patients treated with rituximab had 4-year PFS and OS rates of 81.0% and 100%, 
respectively. Given that combined modality treatment, EFRT, and IFRT resulted in 
equivalent PFS and OS, the authors recommended that IFRT be the standard of care as it 
would likely result in the least toxicity.
A recent retrospective study reported outcomes in 113 patients with stage I to II lymphocyte-
predominant HL, of whom 93 were treated with RT alone, 13 were treated with combined 
modality therapy, and 7 were treated with chemotherapy alone.65 The addition of 
chemotherapy to RT did not appear to improve OS or PFS. Most patients who received 
chemotherapy alone developed early relapse and required salvage. Among patients receiving 
RT alone, there was no difference in OS or PFS among those treated with limited-field RT 
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such as IFRT (median dose, 32 Gy), regional RT such as mantle (median dose, 36Gy), or 
EFRT (median dose, 38 Gy).
These retrospective studies indicate that IFRT to 30 Gy will likely provide excellent 
outcomes in patients with NLPHL, with less toxicity than EFRT or combined modality 
therapy. Furthermore, rather than using antiquated involved fields based on bony anatomy, 
we recommend using the ILROG’s volume-based ISRT guidelines with CT planning for 
NLPHL as well. Consistent with the guidelines, the volumes for NLPHL include a more 
generous margin (potentially including adjacent lymph nodes) compared with ISRT for 
classical HL.
Recently, because the malignant cells of NLPHL express CD20, targeted therapy with 
rituximab has been studied. The GHSG reported on 28 patients with favorable stage IA 
disease treated with 4 once-per-week standard doses (375 mg/m2) of rituximab. As expected, 
toxicity was limited and after a median of 43 months OS was 100%; however, 25% of the 
patients had relapsed.66 Another phase II trial that evaluated the same 4-week course of 
rituximab with and without the addition of maintenance therapy delivered every 6 months 
for 2 years reported similar findings in patients with previously untreated stage I to II 
disease; estimated 5-year PFS and OS were 56% and 87.5%, respectively.67 Despite the fact 
that rituximab is clearly an active agent in NLPHL, these 2 studies suggest that rituximab 
responses are not durable, and results are clearly inferior to RT for patients with newly 
diagnosed early-stage disease (Tables 6, 7).
SUMMARY OF RECOMMENDATIONS
• The standard of care for favorable stage I to II HL is combined modality therapy 
consisting of 2 to 4 cycles of ABVD chemotherapy followed by 20 to 30 Gy of 
ISRT. For patients with early-stage favorable disease who fit the GHSG favorable 
criteria, 2 cycles of ABVD followed by 20-Gy IFRT is adequate. For patients 
with early-stage favorable disease who fit the EORTC criteria but not the GHSG 
criteria, 3 to 4 cycles of ABVD followed by 30-Gy IFRT is recommended.
• The standard radiation treatment volume is ISRT. RT delivery with intensity-
modulated RT, proton therapy, and techniques such as respiratory gating may 
further reduce the radiation dose to normal structures.
• Changing chemotherapy or omitting RT based on PET response for early-stage 
patients may be appropriate with caution after careful consideration and 
preferably as part of a clinical trial, at least until preliminary data mature.
• The standard of care for stage I to II lymphocyte-predominant HL is ISRT with 
more generous treatment volumes than classic HL according the ILROG 
guidelines to a dose of 30 to 36 Gy. Chemotherapy followed by ISRT may be 
appropriate in stage II disease.
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TABLE 1.
Criteria for Favorable Prognosis Hodgkin Lymphoma
Risk Factor EORTC GHSG NCCN
Mediastinal mass MTR <0.35 MMR <0.33 MMR <0.33
ESR and B symptoms ESR <50mm/h if A; ESR <30 mm/h 
if B
ESR <50mm/h if A; ESR <30 mm/h 
if B
ESR <50 mm/h and no B 
symptoms
No. nodal sites involvement ≤3 sites of involvement ≤2 sites of involvement ≤3 sites of
Extranodal involvement — Not permitted —
Age (y) <50 — —
Bulk — — ≤10 cm
EORTC indicates the European Organisation for Research and Treatment of Cancer; ESR, erythrocyte sedimentation rate; GHSG, The German 
Hodgkin Study Group; MMR, mediastinal mass ratio; MTR, mediastinal tumor ratio; NCCN, National Comprehensive Cancer Network.
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TABLE 2.
A 25-Year-Old Woman With Stage IIA Nodular Sclerosing Hodgkin Lymphoma With Left Supraclavicular 
and Mediastinal (3 cm in Widest Diameter) Involvement; Normal ESR, Interim PET/CT is negative (Deauville 
2)
Treatment Rating Comments
Radiation alone 2 RT alone is appropriate only if there are significant contraindications to chemotherapy
Chemotherapy and ISRT 8




 Stanford V (8 wk course) 7
 Stanford V (12wk course) 3
Duration of ABVD (if chemotherapy given alone)
 2 cycles 2
 3-4 cycles 5
 6 cycles 7
Duration of ABVD (combined modality)
 2 cycles 8
 4 cycles 6
 6 cycles 3
Dose of RT (combined modality)
 20 Gy (with ABVD) 8
 30 Gy (with ABVD) 5 This option may be appropriate but there was disagreement among panel members on the 
appropriateness rating as defined by the panel’s median rating
 30 Gy (with Stanford V) 7
Rating scale: 1, 2, 3 usually not appropriate; 4, 5, 6 may be appropriate; 7, 8, 9 usually appropriate.
ABVD indicates doxorubicin, bleomycin, vinblastine, and dacarbazine; ESR, erythrocyte sedimentation rate; IFRT, involved field radiation therapy; 
ISRT, involved site radiation therapy; PET/CT, positron emission tomography/computed tomography; RT, radiation therapy.
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TABLE 3.
A 25-Year-Old Woman With Stage IIA Nodular Sclerosing Hodgkin Lymphoma With Left Supraclavicular 
and Mediastinal (3 cm in Widest Diameter) Involvement; Normal ESR. Interim PET/CT Reveals Response 
Score as Deauville 3
Treatment Rating Comments
Radiation alone 2
Chemotherapy and ISRT 8




 Stanford V (8 wk course) 7
 Stanford V (12 wk course) 3
Duration of ABVD (if chemotherapy given alone)
 2 cycles 2
 3-4 cycles 4
 6 cycles 7
Duration of ABVD (combined modality)
 2 cycles 7
 4 cycles 7
 6 cycles 4 Six cycles of ABVD may be appropriate if the interim PET/CT was done after cycle 3 or 4
Dose of radiation therapy (combined modality)
 20 Gy (with ABVD) 7
 30 Gy (with ABVD) 6
 30 Gy (with Stanford V) 7
 30 Gy + 6 Gy boost to mediastinum 5
Rating scale: 1, 2, 3 usually not appropriate; 4, 5, 6 may be appropriate; 7, 8, 9 usually appropriate.
ABVD indicates doxorubicin, bleomycin, vinblastine, and dacarbazine; ESR, erythrocyte sedimentation rate; IFRT, involved field radiation therapy; 
ISRT, involved site radiation therapy; PET/CT, positron emission tomography/computed tomography.
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TABLE 4.
A 25-Year-Old Woman With Stage IIA Nodular Sclerosing Hodgkin Lymphoma With Bilateral 




Chemotherapy and ISRT 9
Chemotherapy and IFRT 6
Chemotherapy alone 5 This option may be appropriate but there was disagreement among panel members on the 
appropriateness rating as defined by the panel’s median rating
Type of chemotherapy
 ABVD 9
 Stanford V (8 wk course) 7
 Stanford V (12 wk course) 5
Duration of ABVD (if chemotherapy given alone)
 2 cycles 1
 4 cycles 5 This option may be appropriate but there was disagreement among panel members on the 
appropriateness rating as defined by the panel’s median rating
 6 cycles 7
Duration of ABVD (combined modality)
 2 cycles 5 This option may be appropriate but there was disagreement among panel members on the 
appropriateness rating as defined by the panel’s median rating
 4 cycles 8
 6 cycles 5 This option may be appropriate but there was disagreement among panel members on the 
appropriateness rating as defined by the panel’s median rating
Dose of radiation therapy (combined modality)
 20 Gy 5 This option may be appropriate but there was disagreement among panel members on the 
appropriateness rating as defined by the panel’s median rating
 30 Gy 7
 30 Gy + 6 Gy boost to mediastinum 5
Rating scale: 1, 2, 3 usually not appropriate; 4, 5, 6 may be appropriate; 7, 8, 9 usually appropriate.
ABVD indicates doxorubicin, bleomycin, vinblastine, and dacarbazine; ESR, erythrocyte sedimentation rate; IFRT, involved field radiation therapy; 
ISRT, involved site radiation therapy; PET/CT, positron emission tomography/computed tomography.













Dhakal et al. Page 20
TABLE 5.
A 25-Year-Old Woman With Stage IIA Nodular Sclerosing Hodgkin Lymphoma With Bilateral 
Supraclavicular and Mediastinal (7 cm in Widest Diameter) Involvement; Normal ESR. Interim PET/CT Scan 
Demonstrates Deauville 3 in Mediastinum
Treatment Rating Comments
Chemotherapy and ISRT 9
Chemotherapy and IFRT 6
Chemotherapy alone 6
Duration of ABVD (if chemotherapy given alone)
 2 cycles 2
 4 cycles 5
 6 cycles 7 This option assumes interim PET was negative after 4 cycles of chemotherapy
Duration of ABVD (combined modality)
 2 cycles 5 This option may be appropriate but there was disagreement among panel members on the 
appropriateness rating as defined by the panel’s median rating
 4 cycles 6
 6 cycles 4
Dose of radiation therapy (combined modality)
 20 Gy 5 This option may be appropriate but there was disagreement among panel members on the 
appropriateness rating as defined by the panel’s median rating
 30 Gy 7
 30 Gy + 6 Gy boost to mediastinum 5
Rating scale: 1, 2, 3 usually not appropriate; 4, 5, 6 may be appropriate; 7, 8, 9 usually appropriate.
ABVD indicates doxorubicin, bleomycin, vinblastine, and dacarbazine; ESR, erythrocyte sedimentation rate; IFRT, involved field radiation therapy; 
ISRT, involved site radiation therapy; PET/CT, positron emission tomography/computed tomography.
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TABLE 6.
A 30-Year-Old Man With Nonbulky Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma With 
Right Upper Cervical Involvement
Treatment Rating Comments
ISRT alone 7
Chemotherapy and ISRT 6
IFRT alone 7
Chemotherapy and IFRT 4
Mantle RT alone 1
Chemotherapy alone 3
Mantle para-aortic and splenic RT alone 1
Dose of RT alone
 20 Gy 3
 30-36 Gy 8
 >36 Gy 3
Rating scale: 1, 2, 3 usually not appropriate; 4, 5, 6 may be appropriate; 7, 8, 9 usually appropriate.
IFRT indicates involved field radiation therapy; ISRT, involved site radiation therapy; RT, radiation therapy.













Dhakal et al. Page 22
TABLE 7.
A 30-Year-Old Man With Nonbulky Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma With 
Bilateral Neck Involvement
Treatment Rating Comments
ISRT alone 7 ISRT allows for a field that is very similar to IFRT in this situation
Chemotherapy and ISRT 6
IFRT alone 6
Chemotherapy and IFRT 5
Mantle RT alone 2
Chemotherapy alone 3 This option is appropriate only if there are significant contraindications to RT
Mantle para-aortic and splenic RT alone 1
Dose of RT alone
 20 Gy 3
 30-36 Gy 8
 >36 Gy 3
Rating scale: 1, 2, 3 usually not appropriate; 4, 5, 6 may be appropriate; 7, 8, 9 usually appropriate.
IFRT indicates involved field radiation therapy; ISRT, involved site radiation therapy; RT, radiation therapy.
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